InvestorsHub Logo
Followers 2
Posts 456
Boards Moderated 0
Alias Born 02/21/2012

Re: None

Friday, 09/20/2013 11:08:47 AM

Friday, September 20, 2013 11:08:47 AM

Post# of 428883
Teva announces launch of generic equivalent to NIASPAN in US
Friday, September 20, 2013 01:52:17 PM (GMT)


Teva Pharmaceutical Industries announces launch of the generic equivalent to NIASPAN (niacin extended-release) tablets, 500, 700, and 1000Mg in the US
Teva was first to file, making the product eligible for 180 days of marketing exclusivity
StreetAccount notes NIASPAN is marketed by AbbVie (ABBV) and used with diet to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia


Industries: Biotechnology & Drugs, Major Drugs
Primary Company: TEVA-IL
Related Identifiers: TEVA-IL, ABBV-US, ABT-US
Subjects: Drugs (FDA, CHMP, etc.), Regulatory
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News